You are here

Home » Content

İnsülinoma Tanı ve Tedavisi: Güncel Bakış

Diagnosis and Treatment of Insulinoma: an up-to-date Overview

Journal Name:

  • Abant Tıp Dergisi

Publication Year:

  • 2017
DOI: 
10.5505/abantmedj.2017.24892

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Insulinoma is a rare endocrine tumor derived from pancreatic β–cells and the most common cause of organic hyperinsulinemic hypoglycemia. It is usually a small, solitary, intrapancreatic, and benign tumor. It is generally seen as sporadic cases, but it can also be associated with multiple endocrine neoplasia type 1 syndrome (MEN-1). Distinction between malignant and benign tumor can only made by the presence of metastasis as there are no specific morphologic, biochemical or genetic features distinguishing them. Several invasive and non-invazive procedures are present for localization of tumor. Once the localization of tumor is determined, excision can be curative as more than 90% of insulinomas are benign lesions and enucleation is generally sufficient. The treatment includes systemic chemotherapy, chemoembolization, cryotherapy and peptide radionuclide treatment in cases which cannot be operated.
Bookmark/Search this post with
Abstract (Original Language): 
İnsülinoma, pankreas beta hücrelerinden köken alan nadir görülen bir endokrin tümördür ve organik hiperinsülinemik hipogliseminin en sık nedenidir. Çoğunlukla küçük, soliter, intrapankreatik ve benign bir tümördür. Genellikle sporodik olarak görülür ancak multıpl endokrin neoplazi sendromu (MEN- 1) ile de birliktelik gösterebilir. Malign ve benign tümör ayrımını sağlayan spesifik morfolojik, biyokimyasal veya genetik özellikler olmadığı için malignite tanısı lokal ve uzak metastaz varlığı ile konur. Lokalizasyonda girişimsel ve girişimsel olmayan birçok yöntem mevcuttur. Tümör lokalize edildikten sonra cerrahi tedavi ile tümörün çıkarılması olguların %90’ından fazlası benign olduğu için küratiftir ve genelde enükleasyon yeterli olmaktadır. Opere edilemeyen malign insülinomalarda tedavi sistemik kemoterapi, kemoembolizasyon, kriyoterapi ve peptid radyonüklid tedaviyi içerir.
FULL TEXT (PDF): 
PDF icon arastirmax-insulinoma-tani-tedavisi-guncel-bakis.pdf
  • 1
32
37
  • Turkish

REFERENCES

References: 

1. Service FJ, McMahon MM, O'Brien PC, Ballard DJ.
Functioning insulinoma, incidence, recurrence, and longterm
survival of patients: a 60-year study. Mayo Clin
Proc. 1991 Jul;66(7):711-9.
2. Dixon E, Pasieka JL. Functioning and nonfunctioning
neuroendocrine tumors of the pancreas. Curr Opin
Oncol. 2007 Jan;19(1):30-5.
3. Demeure MJ, Klonoff DC, Karam JH, Duh QY, Clark OH.
Insulinomas associated with multiple endocrine
neoplasia type I: the need for a different surgical
approach. Surgery. 1991 Dec;110(6):998-1004.
4. Whipple AO, Frantz VK. Adenoma of islet cells with
hyperinsulinism: A review. Ann Surg. 1935
Jun;101(6):1299-335.
5. Wilder RM, Allan FN, Power MH,. Robertson H.E.
Carcinoma of the islets of the pancreas: hyperinsulinism
and hypoglycemia. J Am Med Assoc, 89 (1927), pp. 348–
55.
6. Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and
other symptoms in patients with insulinomas. Am J Med.
1999 Mar;106(3):307-10.
7. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM,
Seaquist ER, Service FJ. Endocrine Society. Evaluation and
management of adult hypoglycemic disorders: an
Endocrine Society Clinical Practice Guideline. J Clin
Endocrinol Metab. 2009 Mar;94(3):709-28.
8. Grant CS, van Heerden J, Charboneau JW, James EM,
Reading CC. Insulinoma. The value of intraoperative
ultrasonography. Arch Surg. 1988 Jul;123(7):843-8.
9. Doherty GM, Doppman JL, Shawker TH, Miller DL,
Eastman RC, Gorden P, Norton JA. Results of a
prospective strategy to diagnose, localize, and resect
insulinomas. Surgery. 1991 Dec;110(6):989-96.
10. Noone TC, Hosey J, Firat Z, Semelka RC. İmaging and
localization of islet-cell tumours of the pancreas on CT
and MRI. Best Pract Res Clin Endocrinol Metab. 2005
Jun;19(2):195-211.
11. Mirallié E, Pattou F, Malvaux P, Filoche B, Godchaux JM,
Maunoury V, Palazzo L, Lefebvre J, Huglo D, Paris JC,
Carnaille B, Proye C. Value of endoscopic
ultrasonography and somatostatin receptor scintigraphy
in the preoperative localization of insulinomas and
gastrinomas. Experience of 54 cases. Gastroenterol Clin
Biol. 2002;26(4):360-6.
12. Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T,
Gloor B, Martius F, Maecke H, Reubi JC Glucagon-like
peptide-1 receptor imaging for localization of
insulinomas. J Clin Endocrinol Metab. 2009;94(11):4398-
405.
13. Chee YC, Heng A, Tan KP, Singh GD. A case of insulinoma
diagnosed by plasma insulin, selective pancreatic
angiography and computerised tomography. Ann Acad
Med Singapore. 1981 Apr;10(2):221-5.
14. Kinoshita Y, Nonaka H, Suzuki S, Kondo T, Chihara K,
Chiba T, Fujita T, Kotoura Y, Yamamura T. Accurate
localization of insulinoma using percutaneous
transhepatic portal venous sampling--usefulness of
simultaneous measurement of plasma insulin and
glucagon levels. Clin Endocrinol (Oxf). 1985
Nov;23(5):587-93.
15. Zimmer T, Scherübl H, Faiss S, Stölzel U, Riecken EO,
Wiedenmann B. Endoscopic ultrasonography of
neuroendocrine tumours. Digestion. 2000;62 Suppl 1:45-
50.
16. Placzkowski KA, Vella A, Thompson GB, Grant CS, Reading
CC, Charboneau JW, Andrews JC, Lloyd RV, Service FJ.
Secular trends in the presentation and management of
functioning insulinoma at the Mayo Clinic, 1987-2007. J
Clin Endocrinol Metab. 2009;94(4):1069-73.
17. Ishii H, Ito T, Moriya S, Horie Y, Tsuchiya M. Insulinoma a
statistical review of 443 cases in Japan. Nihon Rinsho.
1993 Jan;51 Suppl:199-206.
18. Sakurai A, Aizawa T, Katakura M, Sato Y, Kaneko G,
Yoshizawa K, Hashizume K. Insulinoma in a patient with
non-insulin-dependent diabetes mellitus. Endocr J. 1997
Aug;44(4):473-7.
19. Ravnik-Oblak M, Janez A, Kocijanicic A. Insulinoma
induced hypoglycemia in a type 2 diabetic patient.Wien
Klin Wochenschr. 2001 Apr 30;113(9):339-41.
20. Lablanche S, Chobert-Bakouline M, Risse O, Laverrière
MH, Chabre O, Benhamou PY Malignant insulinoma may
arise during the course of type 1 diabetes mellitus: A case
report. Diabetes Metab. 2015 Jun;41(3):258-61.
21. Campos-Olive N, Ferrer-Garcia JC, Safont MJ. Malignant
insulinoma in a patient with type 2 diabetes mellitus.
Acta Endo (Buc). 2010, 6 (1): 103-9.
22. Hirshberg B. Cochran C., Skarulis MC, Libutti SK,
Alexander HR, Wood BJ, Chang R, Kleiner DE, Gorden
P. Malignant insulinoma: spectrum of unusual clinical
features. Cancer 2005 Jul;104(2):264-72.
23. Baudin E, Caron P, Bohas CL, Tabarin A, Mitry E, Reznick
Y, Taieb D, Pattou F, Goudet P, Vezzosi D. Malignant
insulinoma: Recommendations for characterisation and
treatment Ann Endocrinol (Paris). 2013 Dec;74(5-6):523-
33.
24. Nikfarjam, M., Warshaw, A.L., Axelrod, L.V et al.
Improved contemporary surgical management of
insulinomas: a 25-year experience at the Massachusetts
General Hospital. Annals of Surgery, 2008
Jan;247(1):165-72.
25. Shimizu S, Tanaka M, Konomi M, Mizumoto K, Yamaguchi
K. Laparoscopic pancreatic surgery: Current indications
and surgical results. Surgical Endoscopy And Other
Interventional Techniques. March 2004, Volume 18,
Issue 3, pp 402-6.
26. Finlayson E, Clark OH. Surgical treatment of insulinomas.
Surg Clin N Am. 2004;84:775-85.
27. Roche A, Girish BV, de Baere T, Ducreux M, Elias D,
Laplanche A, Boige V, Schlumberger M , Ruffle P.
Prognostic factors for chemoembolization in liver
metastasis from endocrine tumors. HepatoAdemoğlu
E ve ark.
Abant Med J 2017;6(1):32-37 37
gastroenterology 2004, 51(60):1751-56.
28. Siperstein AE, Berber E. Cryoablation, Percutaneous
Alcohol Injection, and Radiofrequency Ablation for
Treatment of Neuroendocrine Liver Metastases. World
Journal of Surgery. World J Surg. 2001 Jun;25(6):693-6.
29. Van Schaik E, van Vliet EI, Feelders RA, Krenning EP, Khan
S, Kamp K, Valkema R, van Nederveen FH, Teunissen JJ,
Kwekkeboom DJ, de Herder WW. Improved control of
severe hypoglycemia in patients with malignant
insulinomas by peptide receptor radionuclide therapy. J
Clin Endocrinol Metab. 2011 Nov;96(11):3381-9.
30. Rougier P, Mitry E. Chemotherapy in the Treatment of
Neuroendocrine Malignant Tu-mors. Digestion.
2000;62(suppl 1):73–8.
31. Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for
insulinoma: a national UK sur-vey Postgrad Med J. 1997
October; 73(864): 640–41.
32. Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J,
Pradere B, Buscail L, Susini C, Caron P. Octreotide in
insulinoma patients: efficacy on hypoglycemia,
relationships with Oc-treoscan scintigraphy and
immunostaining with anti-sst2A and anti-sst5 antibodies.
Eur J En-docrinol. 2005 May;152(5):757-67.
33. Okabayashi T1, Shima Y, Sumiyoshi T, Kozuki A, Ito S,
Ogawa Y, Kobayashi M, Hana-zaki K. Diagnosis and
management of insulinoma.World J Gastroenterol. 2013
Feb 14;19(6):829-37.

Thank you for copying data from http://www.arastirmax.com